CA-CEPTON-TECHNOLOGIES
11.11.2021 15:02:12 CET | Business Wire | Press release
Cepton Technologies, Inc. announced today that it has been named a CES® 2022 Innovation Awards Honoree in the Vehicle Intelligence & Transportation category for its Nova lidar , a miniature, wide field of view lidar sensor for near-range applications. The announcement was made ahead of CES 2022 , a global consumer electronics and consumer technology trade show that will be held from January 5-8 in Las Vegas, NV and digitally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005540/en/
The CES Innovation Awards program, owned and produced by the Consumer Technology Association (CTA)® , is an annual competition honoring outstanding design and engineering in 27 consumer technology product categories. An elite panel of industry expert judges , including members of the media, designers, engineers and more, reviewed submissions based on innovation, engineering and functionality, aesthetic and design. The Nova lidar has been selected among a record high number of submissions to this year’s program, signifying the weight of Nova’s technology and design value for the automotive market.
Nova features a miniature form factor and a wide field of view, making it ideally suited for seamless integration into modern vehicles. With a target volume price point under $100, Nova sets a worldwide benchmark with its unprecedented combination of compactness, field of view coverage and targeted affordability.
Nova is designed to help minimize perception blind spots to enhance advanced driver assistant systems (ADAS) and autonomous driving (AD) capabilities.
It aims to address major gaps in proximity detection of objects with current sensor technologies such as cameras, radars and ultrasonic sensors. Powered by Cepton’s patented Micro Motion Technology (MMT® ) , Nova enables high-resolution 3D imaging to accurately detect small children, on-road objects, protrusions and road edges etc. to help increase vehicle safety and enable a higher level of autonomy. Compared to some other near-range lidars , Nova achieves a higher field of view in both horizontal (120°) and vertical (60°) directions with significantly lower size, power and weight.
Benefiting from the maturity of MMT and Cepton’s proprietary lidar engine ASIC for advanced signal processing, Nova is built to meet the stringent requirements of the automotive industry. An automotive-grade lidar , it supports ASIL-B functional safety and consumes <3.5 W (typical power). Nova can be elegantly embedded all around an automobile to provide a complete 360° view of a vehicle’s immediate surroundings, without disrupting the vehicle’s design aesthetics.
In addition to automotive applications, Nova can also enable autonomous robotics and ground vehicles for industrial applications.
Earlier this year, Nova was a second-place award winner at the 2021 Tech.AD Europe Awards , in the category of Most Innovative Use of Artificial Intelligence & Machine Learning in the Development of Autonomous Vehicles & Respective Technologies.
“The key value proposition of the Nova lidar is its combination of a wide horizontal and vertical field of view, the very compact size, the low power consumption and an attractive volume price,” said Dr. Jun Pei, CEO of Cepton.
“With that, we hope to significantly enhance vehicle safety in everyday passenger cars by making Nova a mass-market lidar solution . In addition, it uses a scaled version of Cepton’s patented MMT architecture that is already in use in the long-range lidars that we are supplying in our major ADAS lidar program with our key OEM customer . We believe that this means that the core technology enabling Nova has reached a high maturity level and is licensable to manufacturing partners, especially automotive Tier 1s .”
Detailed information about the CES 2022 Innovation Awards honorees can be found at CES.tech/innovation . In January 2022, Cepton will join many other honorees in showcasing their products in the Innovation Awards Showcase area at CES 2022. At the Cepton Booth (#5518, LVCC – West Hall), Cepton will also showcase Nova alongside its comprehensive portfolio of lidar solutions for smart mobility , covering automotive and smart infrastructure applications . Please visit the Cepton website for more information.
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan, India and China, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005540/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom